May 27, 2021

Go or no go? Aducanumab’s day of reckoning

Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.

March 16, 2018

Upcoming events – Clementia and Prometic tackle rare diseases

August 14, 2017

Therapy focus – Fibrogen and Galapagos raise lung disease hopes

August 08, 2017

Pamrevlumab comes off the bench to deliver for Fibrogen

April 04, 2011

Pharmasset the stand out small cap performer in first quarter

July 28, 2010

Medicare dialysis rules to re-shape ESA market